PARP Inhibitor Olaparib Increases Progression Free Survival


In an abstract that will be presented at the American Society of Clinical Oncology annual meeting in Chicago this weekend, researchers report that in patients with platinum-sensitive recurrent serous ovarian cancer, olaparib plus paclitaxel plus carboplatin, followed by maintenance treatment with olaparib, resulted in a significant improvement in progression-free survival compared with paclitaxel plus carboplatin alone.

Previous studies, including one presented at ASCO in 2011, showed that olaparib was useful when given as a maintenance therapy after platinum-based chemotherapy.  This new study tested olaparib as part of the initial treatment regimen, as well as for maintenance.

Click here for more information, and here to view the abstract. 

Posted on in Research